Skip to content
Prof. Anthony Chan
MBBS (Lond), MD (CUHK), FRCP (Lond, Edin, Glas), FHKCP, FHKAM (Medicine)
Li Shu Fan Medical Foundation Professor of Clinical Oncology
Chief Director, Phase I Clinical Trial Centre
Director, Sir YK Pao Centre for Cancer, Prince of Wales Hospital
Cluster Coordinator (Clinical Oncology), New Territories East Cluster
Director, The Hong Kong Cancer Institute
Associate Director, State Key Laboratory of Translational Oncology

Pro-Vice-Chancellor / Vice-President
Master, Wu Yee Sun College

Specific Research / Sites of Interest

Clinical and translational research in Nasopharyngeal Carcinoma (NPC)

Short Biography

Professor Anthony Chan is Li Shu Fan Professor of Clinical Oncology, Director of the Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Chief Director of Phase 1 Clinical Trial Centre, Associate Director of State Key Laboratory of Translational Oncology, Dean of Graduate School and Master of Wu Yee Sun College at The Chinese University of Hong Kong. Professor Chan conducted pivotal studies setting new treatment standard in multimodality approaches in nasopharynx cancer, developed the clinical application of the biomarker EBV DNA and pioneered immunotherapeutic and targeted therapeutics in this disease. He has published over 400 peer-reviewed papers, 57 book chapters and reviews, and delivered over 180 international lectures. He has served on the Editorial Board of Journal of Clinical Oncology and has been Associate Editor of Annals of Oncology since 2014

Most Representative Publications

1. Hui E.P., Li W.F., Ma B.B., Lam W.K.J., Chan K.C.A., Mo F., Ai Q.Y.H., King A.D., Wong C.H., Guo R., Poon D.M.C., Tong M., Li L., Lau T.K.H., Wong K.C.W., Lam D.C.M., Lo Y.M.D., Chan A.T.C. (2020). Integrating postradiotherapy plasma Epstein – Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol, S0923-7534(20), 36376-6
2. Chen Y.P., Chan A.T.C., Le Q.T., Blanchard P., Sun Y., Ma J. (2019) Nasopharyngeal carcinoma. Lancet, 394(10192), 64-18.
3. Lam W.K.J., Jiang P., Chan K.C.A., Peng W., Shang H., Heung M.M.S., Cheng S.H., Zhang H., Tse O.Y.O., Raghupathy R., Ma B.B.Y., Hui E.P., Chan A.T.C., Woo J.K.S., Chiu R.W.K., Lo Y.M.D. (2019). Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nat Commun, 10, 3256
4. Chan A.T.C., Hui E.P., Ngan R.K.C., Tung S.Y., Cheng A.C.K., Ng W.T., Lee V.H.F., Ma B.B.Y., Cheng H.C., WONG F.C.S., Loong H.H.F., Tong M., Poon D.M.C., Ahuja A., King A.D., Wang K., Mo F., Zee B.C.Y., Chan K.C.A., Lo Y.M.D. (2018). Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. J Clin Oncol, 36(31), 3091-100.
5. Ma B.B.Y., Lim W.T., Goh B.C., Hui E.P., Lo K.W., Pettinger A., Foster N.R., Riess J.W., Agulnik M., Chang A.Y.C., Chopra A., Kish J.A., Chung C.H., Adkins D.R., Cullen K.J., Gitlitz B.J., Lim D.W., To K.F., Chan K.C.A., Lo Y.M.D., King A.D., Erlichman C., Yin J., Costello B.A., Chan A.T.C. (2018). Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol, 36(14), 1412-8.
6. Chan K.C.A., Woo J.K.S., King A., Zee B.C.Y., Lam W.K.J., Chan S.L., Chu S.W.I., Mak C., Tse I.O.L., Leung S.Y.M., Chan G, Hui E.P., Ma B.B.Y., Chiu R.W.K., Leung S.F., van Hasselt A.C., Chan A.T., Lo Y.M.D. (2017). Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med, 377(6), 513-22.
7. Li, Y.Y., Chung G.T., Lui V.W., To K.F., Ma B.B., Chow C., Woo J.K., Yip K.Y., Seo J., Hui E.P., Mak M.K., Rusan M., Chau N.G., Or Y.Y., Law M.H., Law P.P., Liu Z.W., Ngan H.L., Hau P.M., Verhoeft K.R., Poon P.H., Yoo S.K., Shin J.Y., Lee S.D., Lun S.W., Jia L., Chan A.W., Chan J.Y., Lai P.B., Fung C.Y., Hung S.T., Wang L., Chang A.M., Chiosea S.I., Hedberg M.L., Tsao S.W., van Hasselt A.C., Chan A.T., Grandis J.R., Hammerman P.S., Lo K.W. (2017). Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun, 8, 14121.
8. Chua M.L.K., Wee J.T.S., Hui E.P., Chan A.T.C. (2016). Nasopharyngeal carcinoma. Lancet, 387(10022), 1012-24.
9. Blanchard P., Lee A., Marguet S., Leclercq J., Ng W.T., Ma J., Chan A.T., Huang P.Y., Benhamou E., Zhu G., Chua D.T., Chen Y., Mai H.Q., Kwong D.L., Cheah S.L., Moon J., Tung Y., Chi k.H., Fountzilas G., Zhang L., Hui E.P., Lu T.X., Bourhis J., Pignon J.P., MAC-NPC Collaborative Group. (2015). Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol, 16(6), 645-55.
10. Mesia R., Henke M., Fortin A., Minn H., Yunes Ancona A.C., Cmelak A., Markowitz A.B., Hotte S.J., Singh S., Chan A.T., Merlano M.C., Skladodwski K., Zhang A., Oliner K.S., VanderWalde A., Giralt J. (2015). Chemmradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomized, controlled, open-label phase 2 trial. Lancet Oncol, 16(2), 208-20.
11. Lee A.W.M, Ma B.B.Y., Ng W.T., Chan A.T.C. (2015). The management of nasopharyngeal carcinoma – current practice and future perspective. J Clin Oncol, 33(29), 3356-64.
12. Leung S.F., Chan K.C., Ma B.B., Hui E.P., Mo F., Chow K.C., Leung L., Chu K.W., Zee B., Lo Y.M., Chan A.T. (2014). Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol, 25(6), 1204-8.